{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arzoxifene",
    "query": {
      "intervention": "Arzoxifene"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-11T03:34:30.863Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00085956",
      "title": "Effects of Arzoxifene on Bone Mass and the Uterus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Postmenopausal Bone Loss"
      ],
      "interventions": [
        {
          "name": "Arzoxifene",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 60 Years · Female only"
      },
      "enrollment_count": 300,
      "start_date": "2004-04",
      "completion_date": "2007-02",
      "has_results": false,
      "last_update_posted_date": "2007-03-09",
      "last_synced_at": "2026-09-11T03:34:30.863Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00085956"
    },
    {
      "nct_id": "NCT00003428",
      "title": "Hormone Therapy in Treating Women With Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "arzoxifene hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 114,
      "start_date": "1998-05",
      "completion_date": "2001-06",
      "has_results": false,
      "last_update_posted_date": "2013-06-24",
      "last_synced_at": "2026-09-11T03:34:30.863Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003428"
    },
    {
      "nct_id": "NCT00190697",
      "title": "A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Breast Cancer",
        "Endometrial Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "arzoxifene",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 70,
      "start_date": "2001-01",
      "completion_date": "2007-04",
      "has_results": false,
      "last_update_posted_date": "2007-05-25",
      "last_synced_at": "2026-09-11T03:34:30.863Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00190697"
    },
    {
      "nct_id": "NCT00005886",
      "title": "Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "arzoxifene hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "tamoxifen citrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 120 Years · Female only"
      },
      "enrollment_count": null,
      "start_date": "2000-07",
      "completion_date": "2002-08",
      "has_results": false,
      "last_update_posted_date": "2017-01-13",
      "last_synced_at": "2026-09-11T03:34:30.863Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005886"
    },
    {
      "nct_id": "NCT00003669",
      "title": "Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "arzoxifene hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": null,
      "start_date": "1998-11",
      "completion_date": "2001-04",
      "has_results": false,
      "last_update_posted_date": "2012-06-07",
      "last_synced_at": "2026-09-11T03:34:30.863Z",
      "location_count": 10,
      "location_summary": "Pasadena, California • Columbia, Missouri • St Louis, Missouri + 6 more",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Columbia",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003669"
    },
    {
      "nct_id": "NCT00003670",
      "title": "Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Primary Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "arzoxifene hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": null,
      "start_date": "1998-10",
      "completion_date": "2001-01",
      "has_results": false,
      "last_update_posted_date": "2012-06-07",
      "last_synced_at": "2026-09-11T03:34:30.863Z",
      "location_count": 4,
      "location_summary": "Columbia, Missouri • Chapel Hill, North Carolina • Abington, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Columbia",
          "state": "Missouri"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Abington",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003670"
    },
    {
      "nct_id": "NCT00088010",
      "title": "Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteoporosis, Postmenopausal"
      ],
      "interventions": [
        {
          "name": "Arzoxifene",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "85 Years",
        "sex": "FEMALE",
        "summary": "60 Years to 85 Years · Female only"
      },
      "enrollment_count": 9369,
      "start_date": "2004-06",
      "completion_date": "2009-11",
      "has_results": false,
      "last_update_posted_date": "2010-06-02",
      "last_synced_at": "2026-09-11T03:34:30.863Z",
      "location_count": 1,
      "location_summary": "Elk Grove, Illinois",
      "locations": [
        {
          "city": "Elk Grove",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00088010"
    },
    {
      "nct_id": "NCT00034125",
      "title": "Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "LY353381",
          "type": "DRUG"
        },
        {
          "name": "tamoxifen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2006-07-19",
      "last_synced_at": "2026-09-11T03:34:30.863Z",
      "location_count": 4,
      "location_summary": "Miami, Florida • Shreveport, Louisiana • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00034125"
    },
    {
      "nct_id": "NCT00005879",
      "title": "LY353381 in Preventing Breast Cancer in Women With Hyperplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "arzoxifene",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 199,
      "start_date": "2000-08",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-09-11T03:34:30.863Z",
      "location_count": 2,
      "location_summary": "Kansas City, Kansas • Dallas, Texas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005879"
    },
    {
      "nct_id": "NCT00383422",
      "title": "Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteoporosis, Postmenopausal"
      ],
      "interventions": [
        {
          "name": "Arzoxifene",
          "type": "DRUG"
        },
        {
          "name": "Raloxifene",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "50 Years to 75 Years · Female only"
      },
      "enrollment_count": 320,
      "start_date": "2006-10",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2010-01-28",
      "last_synced_at": "2026-09-11T03:34:30.863Z",
      "location_count": 5,
      "location_summary": "Gainesville, Georgia • Urbandale, Iowa • Billings, Montana + 2 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Georgia"
        },
        {
          "city": "Urbandale",
          "state": "Iowa"
        },
        {
          "city": "Billings",
          "state": "Montana"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00383422"
    }
  ]
}